Effects of single and repeated electroconvulsive shock on the social and agonistic behaviour of resident rats

Neuropharmacology

Volumn 44, Issue 7, 2003, Pages 911-925

  Mitchell, P J ^a   Fairhall, S J ^b   Fletcher, A ^c   Redfern, P H ^a  

^a University of Bath   (United Kingdom)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^c DURHAM UNIVERSITY   (United Kingdom)

Author keywords

5 HT2A receptor function; 5 HT2C receptor function; Aggression; DOI; Electroconvulsive shock; mCPP

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY MOVEMENT; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FIGHTING; HEAD MOVEMENT; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEDATION; SOCIAL BEHAVIOR;

EID: 0242500479     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(03)00075-3     Document Type: Article

References (63)

1. Blier P., de Montigny C. Current advances and trends in the treatment of depression. TiPs. 15:1994;220-226.
2. 1A receptor antagonist, WAY 100,635, in the rat. Neuropharmacology. 39:2000;1222-1236.
3. 2A receptor expression. Neuroreport. 6:1995;901-904.
4. Burnet P.W.J., Sharp T., LeCorre S.M., Harrison P.J. Expression of 5-HT receptors and the 5-HT transporter in the rat brain after electroconvulsive shock. Neurosci. Letts. 277:1999;79-82.
5. Butler M.O., Morinobu S., Duman R.S. Chronic electroconvulsive seizures increase the expression of serotonin2 receptor mRNA in rat frontal cortex. J. Neurochem. 61:1993;1270-1276.
6. Caldecott-Hazard S., Morgan D.G., DeLeon-Jones F., Overstreet D.H., Janowsky D. Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. Synapse. 9:1991;251-301.
7. Cowen P.J. Pharmacological challenge tests and brain serotonin function in depressaion during SSRI treatment. Briley M., Montgomery S. Antidepressant Therapy at the Dawn of the Third Millennium. 1998;175-189 Martin Dunitz Ltd. London.
8. Delgado P.L., Moreno F.A., Potter R., Gelenberg A.J. Norepinephrine and serotonin in antidepressant action: evidence from neurotransmitter depletion studies. Briley M., Montgomery S. Antidepressant Therapy at the Dawn of the Third Millennium. 1998;141-161 Martin Dunitz Ltd. London.
9. De Montigny C. Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin. J. Pharmacol. Exper. Ther. 228:1984;230-234.
10. Dixon A.K., Fisch H.U., Huber C., Walser A. Ethological studies in animals and man: their use in psychiatry. Pharmacopsychiatry. 22:(Suppl. 1):1989;44-50.
11. Eisen A. Fluoxetine and desipramine: a strategy for augmenting anti-depressant response. Pharmacopsychiatry. 22:1989;272-273.
12. 2A receptors: A review of in vivo studies. Behav. Brain Res. 73:1996;177-181.
13. Fink M. Indications for the use of ECT. Psychopharmacol Bull. 30:1994;269-275.
14. Freeman C.P., Basson J.V., Crighton A. Double-blind controlled trial of electroconvulsive therapy (E.C.T.) in depressive illness. Lancet. 1:1978;738-740.
15. Gagne G.G. Jr., Furman M.J., Carpenter L.L., Price L.H. Efficacy of continuation ECT and antidepressant drugs compared to long-term antidepressants alone in depressed patients. Am. J. Psychiatry. 157:(12):2000;1960-1965.
16. 2 binding sites in rat cortex. J. Neural. Transmission. 41:(Suppl.):1994;127-134.
17. Grant E.C. An analysis of the social behaviour of the male laboratory rat. Behaviour. 21:1963;260-281.
18. 2 receptor number in frontal cortex. Brit. J. Pharmacol. 80:1983;377-385.
19. 2 receptor number in brain as a probable explanation for the enhanced 5-hydroxytryptamine-mediated behaviour following repeated electroconvulsive shock. Brit. J. Pharmacol. 80:1983;173-177.
20. 2A receptors are active under physiological conditions. Psychopharmacology. 128:1996;198-205.
21. Imlah N.W., Ryan E., Harrington J.A. The influence of antidepressant drugs on the response to electroconvulsive therapy and on subsequent relapse rates. Neuropsychopharmacology. 4:1965;438-442.
22. Johnstone E.C., Deakin J.F., Lawler P., Frith C.D., Steven M., McPherson K., Crow T.J. The Northwick Park electroconvulsive therapy trial. Lancet. 2:1980;1317-1320.
23. Kaplan S.M., Kravetz R.S., Ross W.D. The effects of imipramine on the depressive components of medical disorders. Proc. 3rd World Congr. Psychiat. 2:1961;1362-1367.
24. Kay D.W., Fahy T., Garside R.F. A seven-month double blind trial of amitriptyline and diazepam in ECT-treated depressed patients. Br. J. Psychiatry. 117:1970;667-671.
25. Kellar K.J., Bergstrom D.A. Electroconvulsive shock: Effects on biochemical correlates of neurotransmitter receptors in rat brain. Neuropharmacology. 22:1983;401-406.
26. 1C receptors. Brit. J. Pharmacol. 94:1988;137-147.
27. 1C receptors and their therapeutic relevance. Curr. Opin. Invest. Drugs. 2:1993;317-362.
28. 2C/2B receptor function. Neuropharmacology. 33:(12):1994;1581-1588.
29. Khan A., Cohen S., Dager S., Avery D.H., Dunner D. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. Affect Disord. 17:1989;33-38.
30. Maj J., Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J. Neural. Transmission. 88:1992;143-156.
31. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoz R., Rogoz Z., Skuza G., Tokarski T. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology. 127:1996;73-82.
32. Mitchell P.J. Prediction of antidepressant activity from ethological analysis of agonistic behaviour in rats. Cooper S.J., Hendrie C.A. Ethology and Psychopharmacology. 1994;85-109 J Wiley and Sons Ltd. Chichester.
33. Mitchell P.J., Fletcher A. Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology. 32:1993;1001-1009.
34. Mitchell P.J., Fletcher A. Repeated electroconvulsive shock increases aggressive behaviour in resident rats. Soc. Neurosci. Abstr. 20:1994;385.
35. Mitchell P.J., Fletcher A., Redfern P.H. Is antidepressant efficacy revealed by drug-induced changes in rat behaviour exhibited during social interaction? Neurosci. Biobehav. Rev. 15:1991;539-544.
36. Mitchell P.J., Redfern P.H. Acute and chronic antidepressant drug treatments induce opposite effects in the social behaviour of rats. J. Psychopharmacol. 6:1992;241-257.
37. Mitchell P.J., Redfern P.H. Chronic treatment with clomipramine and mianserin increases the hierarchical position of subdominant rats housed in triads. Behav. Pharmacol. 3:1992;239-247.
38. Mitchell P.J., Redfern P.H. Effects of citalopram and paroxetine on rodent social and agonistic behaviour. J Psychopharmacol. 11:(Suppl.):1997;A41.
39. 1A receptor antagonist, WAY-100635. Behav. Pharmacol. 8:1997;585-606.
40. Mitchell P.J., Redfern P.H. Effects of m-chlorophenylpiperazine and mesulergine on rodent agonistic behaviour. J. Psychopharmacol. 14:(suppl):2000;A32.
41. 2 receptor-mediated head shakes but not brain c-fos induction. Neuropharmacology. 35:1996;303-313.
42. Nowak G., Dulinski J. The effect of repeated treatment with electroconvulsive shock (ECS) on serotonin receptor density and turnover in the rat cerebral cortex. Pharmacol. Biochem. and Behav. 38:1991;691-694.
43. Ogundipe L., Jorsh M., Wain B., Lea J. Onset of clinical improvement of depressive illness following electroconvulsive therapy. Psychiatric. Bull. 23:1999;474-477.
44. Oswald I., Brezinova V., Dunleavy D.L.F. On the slowness of action of tricyclic antidepressant drugs. Brit J Psychiatry. 120:1972;673-677.
45. 1-adrenoceptors and phosphoinositide signalling system in rat brain. Eur. J. Pharmacol-Mol. Pharmacol. Section. 226:1992;303-310.
46. 2 receptors after antidepressant administration in forced swim test and after chronic drug administration. J. Phamacol. Exper. Ther. 246:1988;956-962.
47. Peroutka S.J., Snyder S.H. Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science. 210:1980;88-90.
48. 1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Neurosci. Letts. 115:1990;74-80.
49. Priest R.G., Beaumont G., Raptopoulos P. Suicide, attempted suicide and antidepressant drugs. J. Int. Med. Res. 8:(Suppl. 3):1980;8-13.
50. Rodger C.R., Scott A.I.F., Whalley L.J. Is there a delay in the onset of the antidepressant effect of electroconvulsive therapy? Brit. J. Psychiat. 164:1994;106-109.
51. Sackeim H.A. Central issues regarding the mechansims of action of electroconvulsive therapy: directions for future research. Psychopharmacol. Bull. 30:1994;281-308.
52. Sackeim H.A., Haskett R.F., Mulsant B.H., Thase M.E., Mann J.J., Pettinati H.M., Greenberg R.M., Crowe R.R., Cooper T.B., Prudic J. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomised controlled trial. JAMA. 285:(10):2001;1299-1307.
53. 1A agonists. J. Phamacol. Exper. Ther. 273:1995;101-112.
54. Seager C.P., Bird R.L. Imipramine with electrical treatment in depression: a controlled trial. J. Ment. Sci. 108:1962;704-707.
55. Segman R.H., Shapira B., Gorfine M., Lerer B. Onset and time course of antidepressant action: Psychopharmacological implications of a controlled trial of electroconvulsive therapy. Psychopharmacology. 119:1995;440-448.
56. Small I.F. Inhalant convulsive therapy. Fink M., Kety S., McGaugh J., Williams T.A. Psychobiology of Convulsive Therapy. 1974;Winston, Washington DC.
57. Stockmeier C.A., Kellar K.J. In vivo regulation of the serotonin-2 receptor in rat brain. Life Sci. 38:1986;117-127.
58. Tassin J-P., Darracq L., Blanc G., Trovero F. Integrating the monoamine systems. Briley M., Montgomery S. Antidepressant Therapy at the Dawn of the Third Millennium. 1998;1-18 Martin Dunitz Ltd. London.
59. Vetulani J., Lebrecht U., Pilc A. Enhancement of responsiveness of the central serotonergic system and serotonin-2 receptor density in rat frontal cortex by electroconvulsive treatment. Eur. J. Pharmacol. 76:1981;81-85.
60. Vetulani J., Sulser F. Actions of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP generating system in limbic forebrain. Nature. 257:1975;495-496.
61. Wijkstra J., Nolen W.A., Algra A., van Vliet I.M., Khan R.S. Relapse prevention in major depressive disorder after successful ECT: a literature review and a naturalistic case series. Acta. Psychiatr. Scand. 102:(6):2000;454-460.
62. Willner P. Depression: A Psychobiological Synthesis. 1985;J Wiley & Sons Ltd. Chichester, UK.
63. Willner P., Mitchell P.J. Animal models of depression: a diathesis/stress approach. D'haenen H., den Boer J.A., Willner, P. Biological Psychiatry. 2002;703-726 John Wiley & Sons Ltd. Chichester, UK.